Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Semin Thromb Hemost. 2021 Jul;47(5):589-600. doi: 10.1055/s-0041-1725096. Epub 2021 Apr 20.
Sepsis is a life-threatening condition which develops as a dysregulated immune response in the face of infection and which is associated with profound hemostatic disturbances and in the most extreme cases disseminated intravascular coagulation (DIC). In addition, the fibrinolytic system is subject to alterations during infection and sepsis, and impaired fibrinolysis is currently considered a key player in sepsis-related microthrombus formation and DIC. However, we still lack reliable biomarkers to assess fibrinolysis in the clinical setting. Furthermore, drugs targeting the fibrinolytic system have potential value in sepsis patients with severe fibrinolytic disturbances, but these are still being tested in the preclinical stage. The present review provides an overview of key fibrinolytic changes in sepsis, reviews the current literature on potential laboratory markers of altered fibrinolysis in adult sepsis patients, and discusses future perspectives for diagnosis and treatment of fibrinolytic disturbances in sepsis patients.
脓毒症是一种危及生命的病症,是机体在面对感染时发生失调的免疫反应,其与严重的止血紊乱有关,在极端情况下会发生弥散性血管内凝血(DIC)。此外,感染和脓毒症期间纤维蛋白溶解系统会发生改变,目前认为纤溶受损是脓毒症相关微血栓形成和 DIC 的关键因素。然而,我们仍然缺乏可靠的生物标志物来评估临床环境中的纤溶情况。此外,针对纤维蛋白溶解系统的药物对严重纤维蛋白溶解紊乱的脓毒症患者具有潜在价值,但这些药物仍处于临床前研究阶段。本综述概述了脓毒症中的关键纤维蛋白溶解变化,回顾了关于成人脓毒症患者纤维蛋白溶解改变的潜在实验室标志物的现有文献,并讨论了脓毒症患者纤维蛋白溶解紊乱的诊断和治疗的未来展望。